Praluent for Atherosclerotic cardiovascular disease
Quick answer: Praluent is used for Atherosclerotic cardiovascular disease as part of a pcsk9 inhibitor (monoclonal antibody) treatment regimen. Alirocumab — monoclonal antibody that binds PCSK9, increasing LDL receptor recycling and lowering LDL cholesterol The specific dosing for Atherosclerotic cardiovascular disease is determined by your prescriber based on individual factors.
Why is Praluent used for Atherosclerotic cardiovascular disease?
Praluent belongs to the PCSK9 inhibitor (monoclonal antibody) class. Alirocumab — monoclonal antibody that binds PCSK9, increasing LDL receptor recycling and lowering LDL cholesterol This action makes it useful for treating or managing Atherosclerotic cardiovascular disease in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Praluent is the right choice for a specific patient depends on the type and severity of Atherosclerotic cardiovascular disease, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Atherosclerotic cardiovascular disease
Common adult dosing range: 75-150 mg subcutaneously every 2 weeks. The actual dose for Atherosclerotic cardiovascular disease depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Praluent medicine page.
What to expect
Praluent treatment for Atherosclerotic cardiovascular disease typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Atherosclerotic cardiovascular disease
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Praluent is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all PCSK9 inhibitor (monoclonal antibody) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Praluent
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Praluent full prescribing information · All PCSK9 inhibitor (monoclonal antibody) alternatives
Frequently asked questions
How effective is Praluent for Atherosclerotic cardiovascular disease?
Effectiveness varies by individual response, dose, and severity. Praluent is one of several treatment options for Atherosclerotic cardiovascular disease, supported by clinical evidence within the pcsk9 inhibitor (monoclonal antibody) class. Discuss expected response with your prescriber.
How long do I need to take Praluent for Atherosclerotic cardiovascular disease?
Treatment duration depends on the nature of Atherosclerotic cardiovascular disease — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Praluent when used for Atherosclerotic cardiovascular disease?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Praluent for Atherosclerotic cardiovascular disease?
Yes. Multiple medicines and non-drug options exist for Atherosclerotic cardiovascular disease. Alternatives within the pcsk9 inhibitor (monoclonal antibody) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.